文献速递乳房整形与再造

癌症登记中未分化大细胞淋巴瘤病例的系统性漏报:来自一家综合癌症中心的报告

Systematic under-ascertainment of anaplastic large cell lymphoma cases in cancer registries: report from a comprehensive cancer center.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2024-06-07

该研究回顾了2007至2019年纽约市一家大型综合癌症中心提交至纽约州癌症登记处的ALCL病例,通过分析ICD-O-3编码9714和9702识别病理证实的ALCL的敏感度和特异度,发现仅用9714编码的敏感度为82%、特异度为100%,联合编码敏感度为96%、特异度为44%,结论认为既往基于登记处的流行病学研究可能将ALCL风险低估至少20%。

要点

  • ICD-O-3编码9714识别病理证实ALCL的敏感度为82%、特异度为100%。
  • 联合编码9714/9702的敏感度为96%、特异度为44%。
  • 既往影响FDA监管决策的流行病学研究可能将ALCL风险低估至少20%。

核心结论

  • 既往影响FDA监管决策的流行病学研究可能因癌症登记的系统性漏报而将ALCL风险低估至少20%。
  • 作者鼓励采用能确保充分病例确认的方法更新乳腺ALCL的全球风险估计。

研究设计与样本

  • 回顾性分析2007至2019年纽约市一家大型综合癌症中心提交至纽约州癌症登记处的全部ALCL病例。
  • 共审查47,466例原发癌症患者的2,286,164份病理报告,识别出28例组织学证实的ALCL。
  • 通过计算ICD-O-3编码9714(ALCL)和9702(成熟T细胞淋巴瘤,非特指型[T-NOS])识别病理证实ALCL的敏感度和特异度,评估登记处误诊或漏诊的可能性。

主要发现

  • ICD-O-3编码9714(ALCL)识别病理证实ALCL的敏感度为82%,特异度为100%。
  • 联合编码9714/9702(ALCL/T-NOS)的敏感度为96%,特异度为44%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Breast implant-associated anaplastic large cell lymphoma (ALCL) has been rapidly rising in the US and around the world, leading to a mandated "black-box" label on all silicone- and saline-filled implants by the Food and Drug Administration (FDA). Because regulatory decisions in the US and around the world have been influenced primarily by risk estimates derived from cancer registries, it is important to determine their validity in identifying cases of ALCL. METHOD: We reviewed all cases of ALCL submitted to the New York State Cancer Registry from a large comprehensive cancer center in New York City from 2007 to 2019. To determine the possibility of misdiagnosis or under-diagnosis of ALCL cases reported to cancer registries, we accessed the sensitivity and specificity of the ICD-O-3 codes 9714 (ALCL) and 9702 (Mature T-cell lymphoma, not otherwise specified [T-NOS]) to identify pathologically-proven ALCL. RESULTS: We reviewed 2286,164 pathology reports from 47,466 unique patients with primary cancers. Twenty-eight cases of histologically-proven ALCL were identified. The sensitivity and specificity of the ICD-O-3 code 9714 (ALCL) were 82% and 100%, respectively. The sensitivity of the combined codes 9714/9702 (ALCL/T-NOS) was 96% and the specificity was 44%. CONCLUSION: Previous epidemiological studies that influenced regulatory decisions by the FDA may have systematically underestimated the risk of ALCL by at least 20%. We encourage updated global risk estimates of breast ALCL using methods that ensure adequate case ascertainment.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Kinslow CJ, Kim A, Rohde CH, et al. Systematic under-ascertainment of anaplastic large cell lymphoma cases in cancer registries: report from a comprehensive cancer center. J Plast Reconstr Aesthet Surg. 2024. PMID: 38875872. doi:10.1016/j.bjps.2024.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。